Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions

To investigate whether targeted retinal photocoagulation (TRP) of peripheral non‐perfused areas (NPAs) could prevent the recurrence of macular oedema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal bevacizumab injection (IVB).

[1]  S. Sadda,et al.  Effect of photocoagulation of ischemic areas to prevent recurrence of diabetic macular edema. , 2015, Investigative ophthalmology & visual science.

[2]  A. Mirshahi,et al.  Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six‐month results of a prospective randomized clinical trial , 2015, Acta ophthalmologica.

[3]  Y. Takamura,et al.  The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection. , 2014, Investigative ophthalmology & visual science.

[4]  K. McKeage,et al.  Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion , 2014, Drugs & Aging.

[5]  M. Méndez,et al.  Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study , 2014, Acta ophthalmologica.

[6]  U. Schmidt-Erfurth,et al.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. , 2014, Ophthalmology.

[7]  P. Campochiaro,et al.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. , 2014, Ophthalmology.

[8]  Osamu Sawada,et al.  Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion , 2013, Acta ophthalmologica.

[9]  D. Henson,et al.  Optos‐guided pattern scan laser (Pascal)‐targeted retinal photocoagulation in proliferative diabetic retinopathy , 2013, Acta ophthalmologica.

[10]  M. Michaelis,et al.  Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion , 2012, Acta ophthalmologica.

[11]  Justis P. Ehlers,et al.  Retinal vein occlusion: beyond the acute event. , 2011, Survey of ophthalmology.

[12]  T. Mimura,et al.  Influence of ischemia on visual function in patients with branch retinal vein occlusion and macular edema , 2011, Clinical ophthalmology.

[13]  M. Figueroa,et al.  Results of bevacizumab as the primary treatment for retinal vein occlusions , 2010, British Journal of Ophthalmology.

[14]  Pei-Chang Wu,et al.  Treatment of branch retinal vein occlusion induced macular edema in treatment-naïve cases with a single intravitreal triamcinolone or bevacizumab injection. , 2010, Chang Gung medical journal.

[15]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[16]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[17]  Jean-Pierre Hubschman,et al.  Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. , 2010, Ophthalmology.

[18]  M. Maia,et al.  COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONS: Results of the Pan American Collaborative Retina Study Group at 24 Months , 2009, Retina.

[19]  J. Ahn,et al.  Changes of aqueous vascular endothelial growth factor and interleukin‐6 after intravitreal triamcinolone for branch retinal vein occlusion , 2008, Clinical & experimental ophthalmology.

[20]  S. C. Lee,et al.  Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  U. Schmidt-Erfurth,et al.  Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study , 2008, British Journal of Ophthalmology.

[22]  S. Priglinger,et al.  Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion , 2008, British Journal of Ophthalmology.

[23]  Sharon D. Solomon,et al.  Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  R. Avery,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2007, Retina.

[25]  P. Beer,et al.  VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS , 2006, Retina.

[26]  S. Ozdek,et al.  Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. , 2006, American journal of ophthalmology.

[27]  H. Yamashita,et al.  Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. , 2005, American journal of ophthalmology.

[28]  E. Stefánsson,et al.  Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. , 2000, Investigative ophthalmology & visual science.

[29]  E. Chew,et al.  Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. , 1998, Ophthalmology.

[30]  A. Brucker,et al.  Branch Retinal Vein Occlusion , 2020 .

[31]  G. Coscas,et al.  Prognostic factors for retinal vein occlusion: prospective study of 175 cases. , 1996, Ophthalmology.

[32]  G. Coscas.  [Retinal vein occlusions]. , 1983, La Revue du praticien.

[33]  Ingrid U. Scott,et al.  Retinal vein occlusion. , 2010, British medical journal.

[34]  Thomas K. Hunt,et al.  ON THE TREATMENT OF , 1846 .